Breast cancer

Ipsilateral breast cancer recurrence not all related to primary

Australian research has found that more than 10% of cases of recurrent ductal carcinoma in situ (DCIS) of the breast are de novo tumours that occur independently of the primary lesion and have distinct genetic alterations. A...

Australian research has found that more than 10% of cases of recurrent ductal carcinoma in situ (DCIS) of...
Research

Bispecific antibody offers CTLA-4 blockade without the toxicity

A first-in-human trial of a monovalent bispecific antibody targeting PD-1 and CTLA-4 has found encouraging antitumour activity in patients with advanced solid tumours but without the typical toxicity of high dose CTLA-4 blockade. The phase I, open-label, international study presented at...

A first-in-human trial of a monovalent bispecific antibody targeting PD-1 and CTLA-4 has found encouraging antitumour activity in patients with...
Lung cancer

New era? Neoadjuvant immunochemotherapy confers benefit over chemo alone in NSCLC

The addition of neoadjuvant nivolumab to chemotherapy delivers improved event-free survival and more patients with a pathological complete response than chemotherapy alone in resectable non-small cell lung cancer (NSCLC), new findings show. The CheckMate 816 study, published in the NEJM...

The addition of neoadjuvant nivolumab to chemotherapy delivers improved event-free survival and more patients with a pathological complete response than...